Remove 2023 Remove Heart Disease Remove Pulmonary
article thumbnail

Abstract 4147910: 22q11 Deletion Syndrome: A Potenitial Risk Factor For Left Pulmonary Artery Hypoplasia and Need For Intervention in Patients With Congeital Heart Disease

Circulation

Animal studies have shown that mice with TBX1 gene mutations have smaller left pulmonary arteries compared to wild type mice, defined by a reduced left pulmonary artery (LPA) to right pulmonary artery (RPA) ratio. A single study has shown this translates to humans with 22q11 and structurally normal hearts.

article thumbnail

Hot Topics in Congenital and Pediatric Cardiology in the Year 2023

American College of Cardiology

This year saw exciting developments in the treatment of pediatric and congenital heart disease. Transcatheter pulmonary valve replacement (TPVR) continued to dominate the field of interventional cardiology.

article thumbnail

Transpulmonary Expression of Exosomal microRNAs in Idiopathic and Congenital Heart Disease–Related Pulmonary Arterial Hypertension

Journal of the American Heart Association

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundPulmonary artery hypertension (PAH) is a fatal disease characterized by a complex pathogenesis. Transpulmonary exosomal miRs offer valuable insights into pulmonary circulation microenvironments.

article thumbnail

Transcatheter Palliation With Pulmonary Artery Flow Restrictors in Neonates With Congenital Heart Disease: Feasibility, Outcomes, and Comparison With a Historical Hybrid Stage 1 Cohort

Circulation: Cardiovascular Interventions

Background:Neonates with complex congenital heart disease and pulmonary overcirculation have been historically treated surgically. Pulmonary arteries grew adequately for age, and devices were easily removed without complications. However, subcohorts may benefit from less invasive procedures. kilograms [IQR, 2.1–3.3])

article thumbnail

Omics and Extreme Phenotyping Reveal Longitudinal Association Between Left Atrial Size and Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension

Journal of the American Heart Association

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundLeft heart disease is the most common cause of pulmonary hypertension (PH) and is frequently accompanied by increases in pulmonary vascular resistance.

article thumbnail

Avocados for the Heart; Cardiology's Sad State; CBD for Pulmonary Hypertension?

Heart 2023 Conference

Stroke) A Danish study indicated that combining nitrates and PDE5 inhibitors isn't always a terrible idea for men with ischemic heart disease and erectile dysfunction. JACC: Asia) Lexaria Bioscience has announced that a CBD product beats a placebo in simulating acute pulmonary hypertension.

article thumbnail

Medtronic Receives FDA Approval of Mapping and Ablation System and Catheter

DAIC

The PulseSelect Pulsed Field Ablation System, which was FDA approved in December 2023, offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) while the Affera Sphere-9 catheter enables physician treatment flexibility with its wide area focal design and 9mm lattice tip that can used with an 8.5Fr sheath.